Ra Medical Systems Inc. (RMED) and NovoCure Limited (NASDAQ:NVCR) Comparing side by side

Both Ra Medical Systems Inc. (NYSE:RMED) and NovoCure Limited (NASDAQ:NVCR) are each other’s competitor in the Medical Appliances & Equipment industry. Thus the compare of their profitability, analyst recommendations, risk, dividends, earnings and valuation, institutional ownership.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Ra Medical Systems Inc. 5 6.06 N/A -2.73 0.00
NovoCure Limited 50 24.50 N/A -0.59 0.00

Demonstrates Ra Medical Systems Inc. and NovoCure Limited earnings per share (EPS), top-line revenue and valuation.

Profitability

Table 2 represents Ra Medical Systems Inc. (NYSE:RMED) and NovoCure Limited (NASDAQ:NVCR)’s return on equity, return on assets and net margins.

Net Margins Return on Equity Return on Assets
Ra Medical Systems Inc. 0.00% 0% 0%
NovoCure Limited 0.00% -47.2% -16.5%

Liquidity

Ra Medical Systems Inc.’s Current Ratio is 11.6 while its Quick Ratio is 11.3. On the competitive side is, NovoCure Limited which has a 4.7 Current Ratio and a 4.4 Quick Ratio. Ra Medical Systems Inc. is better positioned to pay off short and long-term obligations compared to NovoCure Limited.

Analyst Recommendations

Ra Medical Systems Inc. and NovoCure Limited Ratings and Recommendations are available on the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Ra Medical Systems Inc. 0 0 0 0.00
NovoCure Limited 0 1 1 2.50

Competitively NovoCure Limited has a consensus target price of $62.5, with potential downside of -9.26%.

Insider and Institutional Ownership

The shares of both Ra Medical Systems Inc. and NovoCure Limited are owned by institutional investors at 32.5% and 72.3% respectively. 2.1% are Ra Medical Systems Inc.’s share held by insiders. On the other hand, insiders held about 1.8% of NovoCure Limited’s shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Ra Medical Systems Inc. 1.47% 8.12% -40.66% -53.65% 0% -48.05%
NovoCure Limited 3.57% 8.14% -5.63% 48.55% 64.2% 47.13%

For the past year Ra Medical Systems Inc. had bearish trend while NovoCure Limited had bullish trend.

Summary

NovoCure Limited beats Ra Medical Systems Inc. on 5 of the 8 factors.

NovoCure Limited engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) for the treatment of solid tumors. The company markets its proprietary therapy, TTFields delivery system under the Optune name for use as a monotherapy treatment for adult patients with glioblastoma brain cancer. It is also involved in conducting clinical trials for the use of TTFields in brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer, and mesothelioma. The company markets its products in the United States, Germany, Switzerland, Japan, and other countries. NovoCure Limited was founded in 2000 and is based in Saint Helier, the Channel Islands.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.